HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.

Abstract
Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) have been proposed as a novel therapeutic approach for the treatment of Parkinson's disease. However, evaluation of this proposal has been limited by the availability of appropriate pharmacological tools to interrogate the target. In this study, we describe the properties of a novel mGluR4 PAM. 5-Methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine (ADX88178) enhances glutamate-mediated activation of human and rat mGluR4 with EC(50) values of 4 and 9 nM, respectively. The compound is highly selective for mGluR4 with minimal activities at other mGluRs. Oral administration of ADX88178 in rats is associated with high bioavailability and results in cerebrospinal fluid exposure of >50-fold the in vitro EC(50) value. ADX88178 reverses haloperidol-induced catalepsy in rats at 3 and 10 mg/kg. It is noteworthy that this compound alone has no impact on forelimb akinesia resulting from a bilateral 6-hydroxydopamine lesion in rats. However, coadministration of a low dose of L-DOPA (6 mg/kg) enabled a robust, dose-dependent reversal of the forelimb akinesia deficit. ADX88178 also increased the effects of quinpirole in lesioned rats and enhanced the effects of L-DOPA in MitoPark mice. It is noteworthy that the enhancement of the actions of L-DOPA was not associated with an exacerbation of L-DOPA-induced dyskinesias in rats. ADX88178 is a novel, potent, and selective mGluR4 PAM that is a valuable tool for exploring the therapeutic potential of mGluR4 modulation. The use of this novel tool molecule supports the proposal that activation of mGluR4 may be therapeutically useful in Parkinson's disease.
AuthorsEmmanuel Le Poul, Christelle Boléa, Francoise Girard, Sonia Poli, Delphine Charvin, Brice Campo, Julien Bortoli, Abdhelak Bessif, Bin Luo, Amy Jo Koser, Lisa M Hodge, Karen M Smith, Anthony G DiLella, Nigel Liverton, Fred Hess, Susan E Browne, Ian J Reynolds
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 343 Issue 1 Pg. 167-77 (Oct 2012) ISSN: 1521-0103 [Electronic] United States
PMID22787118 (Publication Type: Journal Article)
Chemical References
  • Excitatory Amino Acid Agonists
  • Receptors, Metabotropic Glutamate
  • metabotropic glutamate receptor 4
Topics
  • Allosteric Regulation (drug effects, physiology)
  • Animals
  • Disease Models, Animal
  • Excitatory Amino Acid Agonists (pharmacology, therapeutic use)
  • HEK293 Cells
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Parkinson Disease (drug therapy, physiopathology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Metabotropic Glutamate (agonists, biosynthesis, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: